Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 3:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: HIV Infections
Interventions: Raltegravir + Truvada; Drug
Lead sponsor: David A Wohl, MD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: HIV Infections, Hepatitis B
Interventions: Adefovir dipivoxil, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 15
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions: Acyclovir, Acyclovir placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 3,682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Seattle, Washington

Conditions: Candidiasis, Oral, Eating Disorders, HIV Infections, Speech Disorders
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Observation; Other
Lead sponsor: HIV Vaccine Trials Network; Network
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 7 more

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma, Leukemia, Lymphoma, Tumor Virus Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 1,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 59
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more

Conditions: Drug Interactions, Human Immunodeficiency Virus
Interventions: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: saquinavir [Invirase], Lopinavir/ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 19
States / cities: Hobson City, Alabama • Tucson, Arizona • Berkeley, California + 16 more

Conditions: Hiv, Healthy
Interventions: Observational; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Disease Transmission, Vertical, Vertical Human Immunodeficiency Virus Transmission, HIV Infections
Interventions: Zidovudine, Nevirapine (NVP), Epivir (3TC), Nelfinavir (NFV); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 2 Days
Enrollment: 1,735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 5
States / cities: Long Beach, California • Gainesville, Florida • Jacksonville, Florida + 2 more

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • Worcester, Massachusetts • Minneapolis, Minnesota

Conditions: HIV-1-infection
Interventions: no intervention; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Human Immunodeficiency Virus
Interventions: Raltegravir, Dolutegravir, Colonoscopy with biopsy; Drug · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections, Hepatitis C
Interventions: Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Stress Disorder, Human Immunodeficiency Virus, Fatigue
Interventions: CBSM-SMI, CBSM-SMI control; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 579 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus Infection, Inflammation
Interventions: AWARENESS for Sexual Minorities, Writing tasks; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Raltegravir as Early Therapy in African-Americans Living With HIV Study

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Mapping the Human HIV Chronobiome

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients

Longer-Acting PrEP in Transgender and Gender Diverse Texans

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men